Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of subretinal NGGT001 for Bietti crystalline retinal dystrophy
CTR20240103Phase 2Active
- Sponsor
- Nuojiebei Biotech
- Start
- Mar 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGGT001 in Bietti crystalline dystrophy (BCD), sponsored by Nuojiebei Biotech. Primary endpoints: Adverse events and Best corrected visual acuity. Started Mar 2024; status: active.
02
Drugs
NGGT001
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on CTR20240103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240103.